Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

@article{Crin2016MulticenterPI,
  title={Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.},
  author={Lucio Crin{\`o} and Myung-ju Ahn and F. De Marinis and Harry J. M. Groen and Heather A. Wakelee and Toyoaki Hida and Tony C. W. Mok and David Robert Spigel and E Felip and Makoto Nishio and Giorgio Scagliotti and Fabrice Branle and Chetachi A Emeremni and Massimiliano Quadrigli and Jie Zhang and Alice Tsang Shaw},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2016},
  volume={34 24},
  pages={2866-73}
}
PURPOSE Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-rearranged non-small-cell lung cancer (NSCLC), regardless of brain metastases status and with or without prior therapy with an inhibitor of the ALK protein. Data are presented from a phase II trial (ASCEND-2) in which ceritinib efficacy and safety were evaluated in patients who had ALK-rearranged NSCLC previously treated with at least one platinum-based chemotherapy and who had experienced progression during… CONTINUE READING